Maravai LifeSciences Holdings Inc represents a strong commitment to innovation, excellence, and customer satisfaction. The company's corporate philosophy revolves around advancing global health solutions through cutting-edge technologies and scientific expertise. Maravai LifeSciences Holdings Inc values collaboration, integrity, and accountability, driving their mission to provide transformative products and services to the life sciences industry. With a focus on developing and delivering high-quality reagents, analytical instruments, and customized solutions, Maravai LifeSciences Holdings Inc strives to empower researchers, pharmaceutical companies, and diagnostic laboratories in their pursuit of breakthrough discoveries and medical advancements.

Maravai LifeSciences Holdings Inc is primarily present in the United States.

Maravai LifeSciences Holdings Inc has achieved several significant milestones. Firstly, the company successfully completed its initial public offering (IPO) on July 1, 2020, becoming a publicly traded company on the NASDAQ stock exchange under the ticker symbol MRVI. Additionally, Maravai has made notable acquisitions, such as the acquisition of MockV Solutions in June 2020, expanding its capabilities in viral vector manufacturing for gene and cell therapies. Moreover, Maravai has reported strong financial growth, with its revenue increasing 46% year-over-year in the second quarter of 2021. The company's dedication to innovation and strategic collaborations has positioned Maravai LifeSciences as a prominent player in the biotech industry.

Maravai LifeSciences Holdings Inc is a leading life sciences company specializing in providing critical products to enable the development of drug therapies, diagnostics, and vaccines. Founded in 2014, Maravai has rapidly established itself as a key player in the biopharmaceutical industry. The company focuses on four main business units, including nucleic acid production, biologics safety testing, protein detection, and in-vitro diagnostics. Maravai's history is characterized by continuous innovation, strategic partnerships, and a dedication to advancing global health through cutting-edge solutions. With its exceptional track record and unwavering commitment, Maravai LifeSciences Holdings Inc is poised to create a lasting impact in the life sciences field.

The main competitors of Maravai LifeSciences Holdings Inc in the market include companies such as Thermo Fisher Scientific, Agilent Technologies, and Illumina Inc. These companies also operate in the life sciences industry, offering a wide range of products and services, including laboratory instruments, reagents, and genomic solutions. However, Maravai LifeSciences Holdings Inc distinguishes itself through its expertise in the development of reagents and advanced technologies for the life sciences research community. With its innovative product portfolio and strong market presence, Maravai continues to compete effectively against its rivals in the industry.

Maravai LifeSciences Holdings Inc is primarily active in the biotechnology and life sciences industries.

Maravai LifeSciences Holdings Inc operates as a life sciences company that provides products and services to enable the development of drug therapies, diagnostics, and vaccines. The company's business model focuses on offering a comprehensive range of integrated solutions, including specialized reagents, consumables, software, and assay platforms. By leveraging its expertise in nucleic acid synthesis, bioprocess impurity testing, and protein labeling, Maravai supports the research and development efforts of pharmaceutical and biotechnology companies globally. As a trusted partner for life science applications, Maravai aims to accelerate scientific discoveries and improve patient outcomes through its innovative and customizable products and services.

مُعامل القيمة السوقية إلى الأرباح لـ Maravai LifeSciences Holdings هو ؜-١٣٩٫٨١.

مُعامِل القيمة إلى المبيعات Maravai LifeSciences Holdings هو ٤٫١٣.

نقاط جودة AlleAktien لـ Maravai LifeSciences Holdings هي 1/10.

المتوقعة Maravai LifeSciences Holdings الإيرادات هي ٢٨١٫١١ مليون. USD.

صافي الربح المتوقعة Maravai LifeSciences Holdings هو ؜-٨٫٣١ مليون. USD.

Maravai LifeSciences Holdings Inc. is a specialized biotechnology company focused on the development and manufacturing of products for large-scale biopharmaceutical production, in-vitro diagnostics, and research. The company focuses on developing innovative technologies and products that contribute to improving the health and well-being of humans and animals. It consists of three main areas: TriLink BioTechnologies, Vector Laboratories, and Cygnus Technologies, each specializing in developing products for the biopharmaceutical market. TriLink BioTechnologies manufactures reagents for nucleic acid synthesis and modification, as well as oligonucleotide-based genetics for body fluid analysis. Vector Laboratories is a leading provider of reagents for immunohistochemistry (IHC) and immunocytochemistry (ICC), including antibodies, kits, buffers, and reactivity cards. Cygnus Technologies is a leading manufacturer of products for the analysis of biopharmaceutical proteins, including ELISA kits, antibodies, protein markers, and reagents for protein purification. Maravai LifeSciences Holdings Inc. aims to develop innovative technologies and products that contribute to process improvement and cost savings. The company's products are designed to assist customers in the biopharmaceutical industry in focusing on drug development and therapy. Maravai also continuously invests in research and development to develop new technologies and products, always striving to offer customers the best and most innovative products. Overall, Maravai LifeSciences Holdings Inc. delivers innovative products that help customers in the biopharmaceutical industry optimize processes, maximize efficiency, and reduce costs. The company is committed to constantly evolving its products to provide customers with better solutions. Thanks to its ability to develop and deliver innovative products to its customers, Maravai LifeSciences Holdings Inc. remains a key player in the biopharmaceutical industry.

يوزع Maravai LifeSciences Holdings أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Maravai LifeSciences Holdings في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـMaravai LifeSciences Holdings هو US56600D1072.

رمز WKN لـ Maravai LifeSciences Holdings هو A2QHK8.

الرمز المُختصر لـ Maravai LifeSciences Holdings هو MRVI.

خلال آخر 12 شهراً، دفعت Maravai LifeSciences Holdings توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Maravai LifeSciences Holdings خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Maravai LifeSciences Holdings هي .

Maravai LifeSciences Holdings يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Maravai LifeSciences Holdings دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Maravai LifeSciences Holdings يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Maravai LifeSciences Holdings المُعلن عنها في ١٢‏/٩‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ١٢‏/٩‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١٢‏/٩‏/٢٠٢٤.

في العام 2023، وزعت Maravai LifeSciences Holdings 0 USD كأرباح أسهم.

يتم توزيع أرباح Maravai LifeSciences Holdings بالعملة USD.